The Los Angeles Post
U.S. World Business Lifestyle
Today: March 21, 2025
Today: March 21, 2025

Biohaven surges as genetic disease drug meets main study goal

Biohaven Pharmaceutical Holding Company logo is displayed on screen on floor of NYSE in New York
September 23, 2024
Reuters - Reuters

By Christy Santhosh

(Reuters) -Biohaven's drug for a genetic disease that affects the nervous system met the main study goal, sending its shares up more than 12% as the trial data allayed investor worries following a setback last year.

The company said on Monday it would submit a marketing application to the U.S. Food and Drug Administration (FDA) based on the trial and was prepared for a potential launch in 2025.

In July 2023, the health regulator declined to review the company's marketing application based on a late-stage study of the drug, troriluzole, from 2022, as it had failed to meet the main goal.

"We believe the vast majority of investors had written troriluzole off completely" said Piper Sandler analyst Christopher Raymond.

With a launch next year, Raymond sees U.S. revenue from the drug touching $250 million by 2030.

Troriluzole is part of Biohaven's non-migraine drugs spun off into a new company in 2022, after Pfizer acquired the migraine assets in an $11.6 billion deal.

In the trial, the drug showed 50% to 70% slowing of disease progression in patients with Spinocerebellar Ataxia (SCA) after three years of treatment, the company said on Monday.

SCA is caused by the degeneration of cells in brain and spinal cord and can lead to uncoordinated movement and muscle wasting.

It affects about 15,000 people in the U.S., according to company estimates, and has no approved treatments in the country.

(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Sriraj Kalluvila)

Related Articles

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks Novo Nordisk defends next-gen obesity drug CagriSema, details new trial US FDA approves Vertex's non-opioid painkiller Surprise finding sheds light on what causes Huntington's disease, a devastating fatal brain disorder
Share This

Popular

Business|Europe|Travel|World

The Latest: Hundreds of thousands of passengers face flight cancelations as Heathrow closes

The Latest: Hundreds of thousands of passengers face flight cancelations as Heathrow closes
Business|Economy|Technology|US

Johnson & Johnson plans $55 billion in US investments over the next four years

Johnson & Johnson plans $55 billion in US investments over the next four years
Business|Economy|Europe|Travel|World

โ€˜Hundreds of millionsโ€™ of dollars in losses expected as disruption extends beyond Heathrow Airport

โ€˜Hundreds of millionsโ€™ of dollars in losses expected as disruption extends beyond Heathrow Airport
Business|Europe|Travel|World

What we know about the fire that brought London's Heathrow Airport to a standstill

What we know about the fire that brought London's Heathrow Airport to a standstill

Health

Business|Economy|Health|Political|US

Trump seems to think America needs a recession. Some people are still recovering from the last one

Trump seems to think America needs a recession. Some people are still recovering from the last one
Economy|Election|Health|Political|US

Some voters are pushing back on lawmakers' efforts to overturn citizen ballot initiatives

Some voters are pushing back on lawmakers' efforts to overturn citizen ballot initiatives
Health|Political|Science|US

US vaccine advisory meeting rescheduled for April

US vaccine advisory meeting rescheduled for April
Business|Finance|Health|US

US FDA expands approval for Alnylam's drug to treat rare heart disease

US FDA expands approval for Alnylam's drug to treat rare heart disease